Muscle wasting treatment with stem cells; It is a biological therapy method that aims to support muscle tissue, which is weakened and destroyed due to the inability to produce muscle proteins as a result of genetic mutations, with the restorative power of mesenchymal stem cells.
This treatment aims to slow down the rate of destruction by suppressing chronic inflammation in muscle fibers and maintain the patient’s mobility for the longest possible time.
According to Assoc. Prof. Dr. Erdinç Özek, stem cell applications not only preserve existing muscle mass in muscle wasting, but also create a functional barrier by preventing the formation of fat and connective tissue (fibrosis) that replaces muscle tissue.
What is Muscle Wasting (Muscular Dystrophy)?
Muscular Dystrophy (MD) is a group of genetic diseases that cause muscles to weaken and melt over time due to the deficiency or faulty production of proteins that protect the structure of muscle fibers.
As the disease progresses, damaged muscle cells are replaced by fat and connective tissue; This causes the muscles to lose their contractile (contraction) ability.
Today, stem cell therapy is used to extend the biological life of muscle tissue by intervening in this breakdown process at the cellular level.
Symptoms and Diagnostic Methods of Muscle Wasting
Although muscle wasting usually begins in early childhood, some types can also occur in adulthood.
- Symptoms: Frequent falls, difficulty getting up from the ground (Gowers’ sign), tiptoe walking, difficulty climbing stairs and false growth of the calf muscles (pseudohypertrophy).
- Diagnostic Methods: CK (Creatine Kinase) blood test, EMG (Electromyography), muscle biopsy and genetic tests are used for definitive diagnosis.
According to Assoc. Prof. Dr. Erdinç Özek, starting stem cell therapy in cases diagnosed early plays a critical role in preventing irreversible loss of muscle tissue (fibrosis).
Types of Muscular Dystrophy: Duchenne (DMD), Becker, and Others
To understand muscular dystrophy, it is important to know which protein deficiency causes the disease.
The table below compares the most common types of muscle wasting and the key focuses of stem cell therapy on these types:
| Type of Disease | Age of Onset | The Fundamental Issue | Stem Cell Treatment Focus |
| Duchenne (DMD) | 3-5 Years | There is no dystrophin protein at all. | Stopping inflammation, slowing down destruction. |
| Becker (BMD) | 5-25 Years | Dystrophin protein is low or faulty. | Maintaining existing muscle strength, prolonging the process. |
| Limb-Girdle (LGMD) | Childhood/Adult | Muscle loss of the shoulder and hip girdle. | Supporting regional muscle regeneration. |
Duchenne Muscular Dystrophy (DMD): It is the most common and fastest progressing type. Stem cell therapy is especially vital here for the protection of the respiratory and heart muscles.
Becker Muscular Dystrophy (BMD): It is milder than DMD; With treatment, the patient’s ability to walk can be preserved for many more years.
Others: In types such as FSHD (face-vertebra-arm) and myotonic dystrophy, it is also aimed to control symptoms.
Clinical Experience Note (Anonymous Case):
In a 7-year-old pediatric patient diagnosed with DMD, two sessions of cord blood-derived mesenchymal stem cells were administered 1 year apart. It was noted that the patient, who needed complete assistance in climbing stairs before treatment, was able to climb 5 steps by holding on to the handrail alone with physical therapy support after treatment, and there was a significant decrease in CK values.
How Does Stem Cell Therapy Work on Muscle Wasting?
When stem cells reach the muscle tissue, they not only complete what is missing, but also prepare a biological environment to change the genetic fate of the muscle.
The main problem in muscular dystrophy is the depletion of the muscle’s ability to repair itself (satellite cell activity); Stem cell therapy breaks the cycle by supporting this depleted reserve from the outside.
According to Assoc. Prof. Dr. Erdinç Özek, the most critical task of stem cells is to create a “biological barrier” in muscle tissue, prevent the destruction of intact muscle fibers and stabilize existing strength.
Restructuring of Muscle Fibers (Regeneration)
In muscle wasting, muscle fibers are constantly broken down and replaced by dysfunctional adipose tissue.
When mesenchymal stem cells are injected into muscle tissue or reach through a vein, they follow damage signals in the area.
These cells secrete growth factors that enable the regeneration of muscle fibers, promoting the division of muscle cells and the formation of new fibers (myotubes).
Reducing Inflammation and Slowing Down Muscle Breakdown
The muscles of a patient with muscular dystrophy are in a constant state of “inflammation”; This inflammation is the main factor that accelerates muscle loss.
Stem cells suppress this harmful inflammation in the muscle thanks to their “immunomodulatory” effects.
- Cutting the Demolition Rate: Thanks to the anti-inflammatory effect, the rate of breakdown of muscle fibers slows down.
- Fibrosis Prevention: It prevents the hardening of muscle tissue (scar tissue formation) and keeps the muscle flexible.
Dystrophin Protein and Cellular Repair Mechanism
The dystrophin protein, which is the main deficiency especially in cases of DMD and BMD, acts as a “shock absorber” that protects the membrane of the muscle fiber.
Stem cells increase the durability of the cell membrane by sending paracrine signals to dystrophin-deficient cells.
Although stem cell therapy is not a gene therapy, the microvesicles (exosomes) secreted by cells carry the molecular instructions necessary for damaged cells to function healthier.
According to Assoc. Prof. Dr. Erdinç Özek; “Time is the biggest enemy in muscle wasting. The sooner we activate cellular repair mechanisms, the more effectively we can slow down the process of muscle transformation into adipose tissue. Our aim in treatment is not only to maintain walking, but also to ensure the general health of the patient by supporting the respiratory muscles.”
The table below summarizes the repair mechanisms of stem cell therapy in muscle tissue and the clinical benefits it provides:
| Cellular Mechanism | Clinical Effect | Expected Result |
| Cytokine Release | Suppression of inflammation | Reduction in muscle aches and cramps |
| Angiogenesis Support | New vessel formation | Better oxygenation and nutrition of the muscle |
| Myogenic Differentiation | Formation of new muscle fibers | Preservation of muscle mass and increase in strength |
Stem Cell Application Methods Used in Muscle Wasting
In systemic diseases such as Muscular Dystrophy, that is, affecting the whole body, the administration of cells with the right strategy is the most important factor that determines the success of the treatment.
Two main pathways are followed in modern medicine for cells to penetrate muscle tissue and initiate a permanent recovery there.
According to Assoc. Prof. Dr. Erdinç Özek, depending on the age of the patient and the stage of the disease, intravenous or direct intramuscular applications (sometimes a combination of the two) are preferred.
Intravenous (Intravenous Access) Administration
Intravenous administration is the most common method, aiming to deliver stem cells into the systemic circulation and reach damaged muscle tissues throughout the body.
Thanks to the ability of stem cells to “homing”, cells given intravenously migrate to damaged muscle fibers by following inflammation signals in the body.
- Advantage: It can reach all muscle groups, including the respiratory muscles and the heart muscle.
- Effect: It systemically slows down the rate of muscle breakdown by lowering chronic inflammation throughout the body.
Intramuscular Injection Techniques
Especially in patients with at-risk walking ability, direct intramuscular injections are administered to support specific areas such as the leg muscles.
In this method, separated stem cells are injected directly into large muscle groups (quadriceps, etc.) that have lost function and a local repair is initiated.
According to Assoc. Prof. Dr. Erdinç Özek, intramuscular injections provide a driving force for the patient to maintain their independence of movement by triggering local regeneration.
Treatment Process and Preparation Phase
Stem cell therapy is not just an injection process, it is a preparation and follow-up process.
- Selection of Cell Source: Depending on the patient’s condition, cells originating from cord blood or bone marrow are determined.
- Laboratory Phase: In laboratories with GMP (Good Manufacturing Practices) standards, cells are multiplied and subjected to viability and quality controls.
- Application: In a sterile clinical environment, transfers are performed in doses calculated according to the patient’s weight.
The table below compares the clinical characteristics of the two main methods of administration:
| Application Method | Focus Point | Purpose of Application |
| Intravenous (IV) | Full Body Muscles | Slowing down systemic destruction and protecting visceral (heart-lung) muscles. |
| Intramuscular (IM) | Specific Muscle Groups | Increasing muscle strength in a specific area (e.g., leg) and preventing tissue loss. |
According to Assoc. Prof. Dr. Erdinç Özek; “It is difficult to say ‘one method is best’ in the treatment of muscle wasting. While we usually provide systemic protection through the vein, we aim for a ‘combined’ success by making local injections to the areas where the patient experiences the most loss of strength. In this way, we both protect internal organ health and support walking capacity.”
Clinical Experience Note (Anonymous Case):
In an 18-year-old young patient diagnosed with Becker Muscular Dystrophy (BMD), a combined (IV + IM) stem cell protocol was applied due to shortening of walking distance. In the physical evaluation performed 5 months after the treatment, it was observed that the patient’s fatigue threshold increased and the cramps he experienced while climbing stairs decreased by 60%.
Which Stem Cell Types Are Used in the Treatment of Muscle Wasting?
The main criterion for the selection of cells used in the treatment of muscle wasting (Muscular Dystrophy) is the capacity of the cells to transform into muscle tissue (myogenic) and stop inflammation.
Today, the most suitable cells for this purpose are mesenchymal stem cells.
According to Assoc. Prof. Dr. Erdinç Özek, the success of the treatment depends not only on the delivery of the cell, but also on the selection of the most appropriate cell source for the patient’s genetic type at the right dose.
Mesenchymal Stem Cells and Muscle Repair
Mesenchymal stem cells (MSCs) are known for their ability to transform into different tissues of the body and send signals to the damaged area.
These cells, which “hear” the signals secreted by damaged cells in muscle tissue, stabilize the membranes of muscle fibers when they reach the area and delay cell death (apoptosis).
In addition, thanks to the “immunomodulatory” effect of these cells, immune system attacks that accompany muscle wasting and accelerate tissue destruction are controlled.
Cord Blood and Bone Marrow-Derived Cells
There are two main sources commonly used in treatment:
- Umbilical Cord (Mesenchymal): They are young and dynamic cells; Their proliferation capacity is very high. It is preferred in cases such as DMD where muscle breakdown is rapid.
- Bone Marrow (Autologous): It is obtained from the patient’s own body. It does not cause tissue compatibility problems and triggers the patient’s own biological repair mechanisms.
Expected Outcomes and Success Rates of Stem Cell Therapy
Since muscle wasting is a genetic and progressive process, expectations from treatment should be based on a realistic basis.
Success; It is not to completely eradicate the disease, but to significantly slow down the rate of destruction and increase functional independence.
The table below summarizes the expected changes in different muscle functions after treatment:
| Assessed Area | Expected Change | Watch Time |
| Inflammation (CK Value) | Decrease in blood values and stabilization | 1 – 3 Months |
| Muscle Flexibility | Reduction in stiffness, relief of cramps | 2 – 4 Months |
| Motor Skill | Increased mobility, prolongation of fatigue time | 6 – 12 Months |
Changes in Muscle Strength and Mobility
After treatment, it is observed that the “fatigue threshold” increases in most patients.
In a child who used to feel the need to rest when walking 10 meters, the extension of this distance and the more stable steps are an important indicator of success.
According to Assoc. Prof. Dr. Erdinç Özek, intramuscular applications of stem cells can delay the transition to a wheelchair by providing local strengthening, especially in the upper leg and hip girdle muscles.
Contribution to Quality of Life and Follow-up of the Process
Stem cell therapy provides not only physical but also systemic improvement.
- Respiratory Support: Improvement in respiratory capacity thanks to the protection of the diaphragm muscles.
- Swallowing and Speaking: In some cases, difficulty swallowing and positive improvements in speech clarity.
[Image showing multidisciplinary follow-up: physical therapy and stem cell synergy]
Frequently Asked Questions
Does the treatment completely end muscle wasting?
Muscle wasting is a genetic disease. Stem cell therapy does not change genetics, but it slows down the process by trying to stop the destruction caused by genetics and repair damaged tissue.
How many doses should be administered?
Depending on the rate of progression of the disease, repeated doses, usually at intervals of 6 months or 1 year, provide a cumulative (cumulative) success.
Are there any side effects of the treatment?
The side effect profile of mesenchymal stem cells is quite low. Mild pain or short-term fever may occur in the application area.
For which age is it suitable?
In fast-progressing types such as Duchenne, the principle of “the sooner, the better” applies. However, it can also be applied to stop the loss of function in adult-type muscle wasting.
Clinical Experience Note (Anonymous Case):
A 12-year-old Becker patient with Muscular Dystrophy (BMD) received stem cell therapy when he began to have difficulty lifting his arms and eating on his own. In the follow-up performed at 6 months after the application, it was determined that the limitation caused by atrophy in the arm muscles decreased and the patient needed less help in daily activities (dressing, eating).
Source and Expert Knowledge:
This article was prepared with Assoc. Prof. Dr. Erdinç Özek’s expertise in orthopedic biological therapies and musculoskeletal regeneration. Assoc. Prof. Dr. Erdinç Özek is a senior medical doctor who pioneered the implementation of advanced cellular therapies within ethical boundaries and scientific standards in Turkey.
